GC
FBIO icon

Guggenheim Capital’s Fortress Biotech FBIO Stock Holding History

Guggenheim Capital’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-743
Closed -$50K – 2743
2017
Q3 		$50K Buy
743
+3
+0.4% +$202 ﹤0.01% 2702
2017
Q2 		$53K Sell
740
-7
-0.9% -$413 ﹤0.01% 2733
2017
Q1 		$41K Buy
+747
New +$33.4K ﹤0.01% 2743
2014
Q3 		– Sell
-1,107
Closed -$29K – 3029
2014
Q2 		$29K Sell
1,107
-440
-28% -$11.6K ﹤0.01% 3134
2014
Q1 		$46K Buy
1,547
+380
+33% +$14.8K ﹤0.01% 3144
2013
Q4 		$46K Buy
1,167
+349
+43% +$13.5K ﹤0.01% 3064
2013
Q3 		$86K Buy
818
+98
+14% +$12K ﹤0.01% 2868
2013
Q2 		$92K Buy
+720
New +$106K ﹤0.01% 2833

Other funds holding FBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
CAM
ClariVest Asset Management San Diego, California $980M AUM 60.89% 1-Year Est. Return
SIM
Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return

Guggenheim Capital's FBIO Position: Q4 2017 in Review

Guggenheim Capital sold out of Fortress Biotech (FBIO) in Q4 2017, closing a stake of 743 shares — an estimated $50K sold.

Guggenheim Capital first reported a position in FBIO in Q2 2013 and held it in 8 quarters. The position peaked at $92K in Q2 2013. 62 funds tracked by Wall St. Rank hold FBIO as of Q4 2017.

  • Guggenheim Capital reported no remaining Fortress Biotech position as of Q4 2017 after selling out during the quarter.
  • Guggenheim Capital sold 743 Fortress Biotech shares in Q4 2017, an estimated $50K.
  • Guggenheim Capital first reported a position in Fortress Biotech in Q2 2013 and held it in 8 quarters.
  • Guggenheim Capital's Fortress Biotech position peaked at $92K in Q2 2013.
  • 62 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2017.

Based on Guggenheim Capital's 13F filing for Q4 2017, filed 14 Feb 2018.